Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Charline Caumont"'
Autor:
Véronique Hofman, MD, PhD, Simon Heeke, PhD, Christophe Bontoux, MD, Lara Chalabreysse, MD, Marc Barritault, MD, PhD, Pierre Paul Bringuier, DVM, Tanguy Fenouil, MD, PhD, Nazim Benzerdjeb, MD, PhD, Hugues Begueret, MD, PhD, Jean Philippe Merlio, MD, PhD, Charline Caumont, MD, Nicolas Piton, MD, PhD, Jean-Christophe Sabourin, MD, PhD, Solène Evrard, MD, PhD, Charlotte Syrykh, MD, Anna Vigier, MD, Pierre Brousset, MD, PhD, Julien Mazieres, MD, PhD, Elodie Long-Mira, MD, PhD, Jonathan Benzaquen, MD, PhD, Jacques Boutros, MD, Maryline Allegra, PhD, Virginie Tanga, MSc, Virginie Lespinet-Fabre, PhD, Myriam Salah, MSc, Christelle Bonnetaud, MSc, Olivier Bordone, MSc, Sandra Lassalle, MD, PhD, Charles-Hugo Marquette, MD, PhD, Marius Ilié, MD, PhD, Paul Hofman, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100457- (2023)
Introduction: Gene fusion testing of ALK, ROS1, RET, NTRK, and MET exon 14 skipping mutations is guideline recommended in nonsquamous NSCLC (NS-NSCLC). Nevertheless, assessment is often hindered by the limited availability of tissue and prolonged nex
Externí odkaz:
https://doaj.org/article/281c42c4a2fc44f5a040454d2f97ad5d
Autor:
Etienne Buscail, Alexandre Chauvet, Pascaline Quincy, Olivier Degrandi, Camille Buscail, Isabelle Lamrissi, Isabelle Moranvillier, Charline Caumont, Severine Verdon, Alain Brisson, Marion Marty, Laurence Chiche, Christophe Laurent, Veronique Vendrely, François Moreau-Gaudry, Aurelie Bedel, Sandrine Dabernat
Publikováno v:
Translational Oncology, Vol 12, Iss 11, Pp 1395-1403 (2019)
Tumor-released extracellular vesicles (EVs) contain tumor-specific cargo distinguishing them from healthy EVs, and making them eligible as circulating biomarkers. Glypican 1 (GPC1)-positive exosome relevance as liquid biopsy elements is still debated
Externí odkaz:
https://doaj.org/article/447e7ab005934ffa9855c3175c2772d0
Autor:
Marie Guicheney, Océane Ducharme, Charline Caumont, Emilie Gerard, Léa Dousset, Marie Beylot-Barry, Jean-Philippe Merlio, Audrey Gros, Anne Pham-Ledard
Publikováno v:
Journal of Investigative Dermatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14071601e2cc185330918bf9e19a2a06
https://doi.org/10.1016/j.jid.2022.12.022
https://doi.org/10.1016/j.jid.2022.12.022
Autor:
Benoit Terris, Jean Roudié, Aude Aline-Fardin, Mélanie Cariou, Claire Bocciarelli, Laurent Doucet, Jean-Philippe Merlio, Laura Samaison, David Cappellen, Charline Caumont, Arnaud Uguen, Pascale Marcorelles
Publikováno v:
Human Pathology. 114:99-109
Summary Targetable kinase fusions are extremely rare ( We searched for NTRK1, NTRK2, NTRK3, ALK, ROS1, BRAF, RET, and NRG1 kinase fusions in CRCs using methods easy-to-implement in pathology laboratories: immunohistochemistry (IHC), fluorescent in si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6d6326ac9591434331ab6abc2cb55ab
https://doi.org/10.1016/j.humpath.2021.05.006
https://doi.org/10.1016/j.humpath.2021.05.006
Autor:
Matthieu Guillard, Charline Caumont, Pascale Marcorelles, Jean-Philippe Merlio, David Cappellen, Arnaud Uguen
Publikováno v:
Journal of Clinical Pathology. :jcp-2023
AimsWe aimed to evaluate the performances of the Idylla GeneFusion Assay (IGFA) designed to detect, in a single, rapid and fully automated assay,ALK,ROS1,RET,NTRK1,NTRK2andNTRK3gene fusions andMETexon 14 skipping in cancer samples.MethodsBased on a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b30a254b2d19f9e5aa9213a1510ab8f
https://doi.org/10.1136/jcp-2023-208798
https://doi.org/10.1136/jcp-2023-208798
Autor:
Pietro Rosellini, Samuel Amintas, Charline Caumont, Rémi Veillon, Sigolène Galland-Girodet, Alain Cuguillière, Laurent Nguyen, Charlotte Domblides, Amandine Gouverneur, Jean-Philippe Merlio, Julien Bezin, Pierre-Olivier Girodet
Publikováno v:
European journal of cancer (Oxford, England : 1990). 172
Mutations in STK11/LKB1 gene present a negative impact on tumour immune microenvironment, especially with concomitant activating KRAS mutation. These recent data may explain a decreased response to immunotherapy treatment in STK11 mutant non-small ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a926dc226500ab537f1d18639b1aac4
https://pubmed.ncbi.nlm.nih.gov/35759814
https://pubmed.ncbi.nlm.nih.gov/35759814
Autor:
Farah Rahal, Caroline Capdevielle, Benoit Rousseau, Julien Izotte, Jean-William Dupuy, David Cappellen, Guillaume Chotard, Mélissa Ménard, Justine Charpentier, Vincent Jecko, Charline Caumont, Edouard Gimbert, Christophe F Grosset, Martin Hagedorn
Publikováno v:
Neuro-Oncology Advances
Neuro-Oncology Advances, Society for NeuroOncology (SNO); the European Association of Neuro-Oncology(EANO); and Oxford University Press, 2022, ahead of print. ⟨10.1093/noajnl/vdac018⟩
Neuro-Oncology Advances, Society for NeuroOncology (SNO); the European Association of Neuro-Oncology(EANO); and Oxford University Press, 2022, 4 (1), ahead of print. ⟨10.1093/noajnl/vdac018⟩
Neuro-Oncology Advances, Society for NeuroOncology (SNO); the European Association of Neuro-Oncology(EANO); and Oxford University Press, 2022, ahead of print. ⟨10.1093/noajnl/vdac018⟩
Neuro-Oncology Advances, Society for NeuroOncology (SNO); the European Association of Neuro-Oncology(EANO); and Oxford University Press, 2022, 4 (1), ahead of print. ⟨10.1093/noajnl/vdac018⟩
Background Diffuse Midline Glioma, H3K27M-mutant (DMG) is a rare, highly aggressive pediatric tumor affecting the brainstem, and is one of the deadliest cancers. Currently available treatment options such as chemotherapy and radiotherapy do only mode
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66276ee997a255b69ab1b22602d10d20
https://www.hal.inserm.fr/inserm-03598538/document
https://www.hal.inserm.fr/inserm-03598538/document
Autor:
Léa Dousset, Florence Poizeau, Caroline Robert, Sandrine Mansard, Laurent Mortier, Charline Caumont, Émilie Routier, Alain Dupuy, Jacques Rouanet, Maxime Battistella, Anna Greliak, David Cappellen, Marie-Dominique Galibert, Clara Allayous, Alexandra Lespagnol, Émilie Gerard, Inès Kerneuzet, Séverine Roy, Caroline Dutriaux, Jean-Philippe Merlio, Beatrice Vergier, Alexa B. Schrock, Jessica Lee, Siraj M. Ali, Solène-Florence Kammerer-Jacquet, Céleste Lebbé, Marie Beylot-Barry, Lise Boussemart
Publikováno v:
JCO Precision Oncology
JCO precision oncology
JCO precision oncology, American Society of Clinical Oncology, 2021, 5, ⟨10.1200/PO.21.00084⟩
JCO precision oncology, 2021, 5 (5), pp.PO.21.00084. ⟨10.1200/PO.21.00084⟩
JCO precision oncology
JCO precision oncology, American Society of Clinical Oncology, 2021, 5, ⟨10.1200/PO.21.00084⟩
JCO precision oncology, 2021, 5 (5), pp.PO.21.00084. ⟨10.1200/PO.21.00084⟩
PURPOSE Emerging evidence suggests a correlation between the tumor mutational burden (TMB) and the response to programmed cell death-1 protein (PD-1) monotherapy across multiple cancer types. In skin cancers, as high TMB is mostly because of ultravio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2710a59cfb32077d16db1c59d0232ed
http://europepmc.org/articles/PMC8691497
http://europepmc.org/articles/PMC8691497
Autor:
Diane Moreau, Eric Huchot, Emilie Foch, Nathalie Allou, Charline Caumont, Jean Philippe Merlio, Michel Andre
Publikováno v:
Respiratory medicine and research. 82
In recent years, the discovery of predictive biomarkers has enabled the development of targeted therapies that have improved the prognosis of patients with non-small cell lung cancer (NSCLC). No data are available at present on the molecular profile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffeb35337643ccca6b4726ca31e5f67c
https://pubmed.ncbi.nlm.nih.gov/35908523
https://pubmed.ncbi.nlm.nih.gov/35908523
Autor:
Catherine Ling, Charline Caumont, Audrey Bidet, Jean-François Viallard, Marie Parrens, Alexandre Guy, Lisa Boureau
Publikováno v:
Virchows Archiv : an international journal of pathology. 479(4)
BCR–ABL-fusion-negative myeloproliferative neoplasms (MPNs) with myelofibrosis (MF) include primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. Clonal extramedullary hematopoiesis (EMH) can occur during MPN pathogenesis. Al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03cc3f79b5b0da06e4d8c4c98fa4ed2f
https://pubmed.ncbi.nlm.nih.gov/33934231
https://pubmed.ncbi.nlm.nih.gov/33934231